Podcast: Play in new window | Download (Duration: 35:17 — 33.2MB) | Embed
Subscribe: Apple Podcasts | Spotify | Amazon Music | Android | Pandora | iHeartRadio | Blubrry | Podcast Index | TuneIn | RSS | More
Threading the needle between being in Academia and founding startups, fostering the next generation of innovators, building an engineer for innovation at King’s College, and amazing advice and perspective with an amazing, world class scientists, innovator, and leader.
Dr. Davide Danovi
Prior to this, he was principal scientist at Progenitor Labs, a novel biotechnology company founded to isolate drugs for regenerative medicine using innovative stem cell technologies.
Before, he worked with Prof. Austin Smith and Dr. Steve Pollard at the University of Cambridge and at University College London where he developed a live image based chemical screening platform to isolate compounds active on human neural stem cells from normal or brain tumour samples.
He holds an MD from University of Milan and a PhD in Molecular Oncology from the European Institute of Oncology where he demonstrated the causative role of the HdmX protein in human cancer.”
Director of Cell Phenotyping Platform at King’s College London
“We work in the framework of the Human Induced Pluripotent Stem Cells Initiative (HipSci) project, funded by the Wellcome Trust and MRC. We provide a dedicated laboratory space for collaborative cell phenotyping to study how intrinsic and extrinsic signals impact on human cells to develop assays for disease modeling and drug discovery and to identify new disease mechanisms.”
Director of HipSci Cell Phenotyping
“HipSci stands for Human Induced Pluripotent Stem Cell Initiative. The project brings together diverse constituents in genomics, proteomics, cell biology and clinical genetics to establish a UK national iPS cell resource (over 500 lines from patients and 500 from healthy individuals) to discover how genomic variation impacts on cellular phenotype and identify new disease mechanisms.
Strong links with NHS investigators will ensure that studies on the disease-associated cell lines will be linked to extensive clinical information. Further key features of the project are an open access model of data sharing; engagement of the wider clinical genetics community in selecting patient samples and provision of dedicated laboratory space for collaborative cell phenotyping and differentiation.”
Amazing and Useful article. thank you